Personalised non-surgical prehabilitation: a feasibility pilot study

• Research type

  Research Study

• Full title

  A personalised prehabilitation model for patients undergoing chemotherapy and/or radiotherapy treatment for lung cancer: A feasibility pilot study.

• IRAS ID

  311755

• Contact name

  Kelly Wade-Mcbane

• Contact email

  k.wade-mcbane@nhs.net

• Sponsor organisation

  Imperial College Healthcare NHS Trust

• ISRCTN Number

  ISRCTN00000000

• Clinicaltrials.gov Identifier

  NCT00000000

• Clinicaltrials.gov Identifier

  22CX7570, ClinicalTrials.gov ID number whilst awaiting NCT number

• Duration of Study in the UK

  0 years, 11 months, 31 days

• Research summary

  Background

  The term ‘prehabilitation’ refers to a period of time before treatment and often includes diet, exercise and/or wellbeing plans to help patients through their cancer treatment. Prehabilitation has shown to benefit patients having surgery, but there is little research into its use in chemotherapy or radiotherapy.

  The UK sees more deaths from lung cancer than any other. 70-80% of lung cancer patients receive chemotherapy or radiotherapy treatment. Treatment side effects can have a significant impact on quality of life. Personalised prehabilitation can take into account the challenges patients face, helping patients through treatment.

  Aim

  To see if a personalised plan of diet, exercise and emotional support can be used in practice for patients having chemotherapy or radiotherapy treatment for lung cancer.
  
  Methods

  The study will involve lung cancer patients from Imperial College Healthcare NHS Trust who are:

  • Over the age of 18 years old
  • Have not had previous lung cancer surgery and
  • Are about to start chemotherapy or radiotherapy treatment

  The prehabilitation interventions will be based upon patient need and readiness, assessed using:

  • A series of questionnaires
  • An assessment of walking
  • A measure of grip strength

  These will be done prior to and at the middle and end of a patient’s chemotherapy and/or radiotherapy treatment. Personalised goals will be agreed at each stage.

  Throughout treatment, patients will be asked to keep a daily diary to record their symptoms, appetite, mobility and mood. The diary will also be used to monitor goal adherence.
  
  Public involvement

  Patients will be part of a study advisory group, helping with research design and dissemination e.g. with the presentation of findings to the lung cancer support group.

  Dissemination
  
  All patients will receive a written summary of findings. Results will be shared in a scientific journal and presented at relevant conferences. Patients will not be identifiable.

• REC name

  London - London Bridge Research Ethics Committee

• REC reference

  22/PR/0390

• Date of REC Opinion

  13 Apr 2022

• REC opinion

  Favourable Opinion